Hydromorphone Versus Prochlorperazine + Diphenhydramine for Acute Migraine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02389829
Recruitment Status : Completed
First Posted : March 17, 2015
Last Update Posted : February 28, 2017
Information provided by (Responsible Party):
Benjamin Friedman, Montefiore Medical Center

Brief Summary:
Opioids are commonly used to treat migraine in North American Emergency Departments. We are comparing efficacy and adverse events of hydromorphone, an opioid, to that of prochlorperazine, a dopamine antagonist with known efficacy in migraine. Prochlorperazine will be combined with diphenhydramine to prevent adverse events.

Condition or disease Intervention/treatment Phase
Migraine Drug: Hydromorphone Drug: Prochlorperazine Drug: Diphenhydramine Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 127 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Hydromorphone Versus Prochlorperazine + Diphenhydramine for Treatment of Acute Migraine. A Randomized, Emergency Department Based, Comparative Efficacy Study
Study Start Date : March 2015
Actual Primary Completion Date : June 2016
Actual Study Completion Date : October 2016

Arm Intervention/treatment
Active Comparator: Hydromorphone
Hydromorphone 1mg, administered as intravenous drip over 5 minutes. Patients can receive second 1mg dose at 1 hour.
Drug: Hydromorphone
Other Name: Dilaudid
Active Comparator: Prochlorperazine

Prochlorperazine 10mg, administered as intravenous drip over 5 minutes. Diphenhydramine 25mg co-administered.

Patients can receive second 10mg dose at 1 hour.

Drug: Prochlorperazine
Other Name: Compazine
Drug: Diphenhydramine
Other Name: Benadryl

Primary Outcome Measures :
  1. Sustained headache relief [ Time Frame: 48 hours ]
    Achieve a headache level of mild or none within two hours of medication administration and maintain a level of mild or none for 48 hours without use of rescue medication

Secondary Outcome Measures :
  1. Rescue medication [ Time Frame: 48 hours ]
    Need for additional medication to treat headache

  2. Short term headache relief/ head freedom [ Time Frame: 2 hours ]
    Achieve level of mild/ none (relief) or none (freedom)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Migraine headache (International Classification of Headache Disorders 3B criteria)

Exclusion Criteria:

  • Brain imaging ordered
  • Fever
  • Objective neurological findings
  • Pregnancy/ breast feeding
  • Allergy/ contraindication to investigational medication
  • History of addiction to opioids, use of methadone, any use of opioids previous 30 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02389829

United States, New York
Montefiore Medical Center--Einstein
Bronx, New York, United States, 10461
Sponsors and Collaborators
Montefiore Medical Center
Principal Investigator: Benjamin W Friedman, MD, MS Albert Einstein College of Medicine, Inc.

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Benjamin Friedman, Associate Professor, Montefiore Medical Center Identifier: NCT02389829     History of Changes
Other Study ID Numbers: HM vs CPZ
First Posted: March 17, 2015    Key Record Dates
Last Update Posted: February 28, 2017
Last Verified: February 2017

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anesthetics, Local
Autonomic Agents
Gastrointestinal Agents
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Hypnotics and Sedatives
Anti-Allergic Agents